LATEST NEWS

Jun-05-2018

Protalix BioTherapeutics Announces Additional Positive Results from Final Analysis of the Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis

Mucosal Improvement Observed in 61% of the Patients and 33% achieved Mucosal Healing Clinical Responses Observed in 67% of the Patients and Clinical Remission Observed in 28% of the Patients 89% of the Patients Experienced a Reduction in Mayo Score, and 61% of the Patients Experienced a Reduction in Endoscopic Sub Score  No Systemic Absorption Observed CARMIEL, Israel, June 05, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today t... 
May-25-2018

Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteristics for Fabry Disease Patients Screened in the Phase III BALANCE Study of Pegunigalsidase Alfa at the 55th ERA-EDTA Congress

Remaining Effective Enzyme in Blood Samples was more than Double for Pegunigalsidase Alfa (PRX-102) Compared to Fabrazyme® as a Result of Higher Inhibition of Neutralizing Antibodies Measured in Fabrazyme CARMIEL, Israel, May 25, 2018 (GLOBE NEWSWIRE) -- GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based ... 
May-24-2018

Protalix Announces Exchange and Discharge of Remaining 2018 Notes

CARMIEL, Israel, May 24, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (the “Company”) (NYSE American:PLX) (TASE:PLX) announced today that $3.42 million of the aggregate principal amount of the Company’s outstanding 4.5% Convertible Senior Notes due 2018 (the “Notes”) will be exchanged for 2,613,636 shares of the Company’s common stock and $2.27 million in cash.  Additionally, the Company announced today that it has delivered the necessary funds under the indenture governing the Note... 
All News